Dataset Information

Antimalarial Activities of Hydromethanolic Crude Extract and Chloroform Fraction of Gardenia ternifolia Leaves in Plasmodium berghei Infected Mice.

ABSTRACT:

Background

Gardenia ternifolia is utilized in traditional medicine of Ethiopia for malaria treatment and possessing in vitro antimalarial activity. However, no in vivo study was conducted to substantiate the claim. The aim of this study was to judge the antimalarial activity of Gardenia ternifolia extract in vivo in Plasmodium berghei-infected mice.

Methods

Plasmodium berghei was inoculated to healthy mice, and hydromethanolic crude extract and chloroform fraction of G. ternifolia leaves at 100?mg/kg/day, 200?mg/kg/day, and 400?mg/kg/day were administered. Percent parasitemia inhibition, percent change in bodyweight, hemoglobin level, and mean survival time were determined. Data were analyzed using one-way ANOVA followed by post hoc Tukey HSD test with IBM SPSS software version 20.0 statistical package and P < 0.05 considered as statistically significant.

Results

The chemosuppressive test of hydromethanolic crude extract at 100?mg/kg/day, 200?mg/kg/day, and 400?mg/kg/day ranged from 27.09% to 67.72%, and chloroform fraction had 35.21%-78.19% parasitemia suppression, respectively. For curative test on day 5, hydromethanolic crude extract at 100?mg/kg/day, 200?mg/kg/day, and 400?mg/kg/day ranged from 25.58% to 48.76%, chloroform fraction at 100?mg/kg/day, 200?mg/kg/day, and 400?mg/kg/day and chloroquine base at 10?mg/kg showed 46.36%-74.42% and 92.87% percent parasitemia inhibition, respectively, and also the results to both tests were highly significant (P < 0.001) compared to the negative control. Maximum effects on chemosuppressive, curative, prevention of weight loss, and reduction in hemoglobin were observed at higher doses of the hydromethanolic crude extract and chloroform fraction.

Conclusion

From this study, hydromethanolic crude extract and chloroform fraction of G. ternifolia leaves have shown promising antimalarial activity. The findings support the traditional claim of G. ternifolia leaves for malaria treatment; however, species variation could also limit such a straightforward extrapolation of the findings of this study in humans.

SUBMITTER: Aragaw TJ

PROVIDER: S-EPMC7785367 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Antimalarial Activities of Hydromethanolic Crude Extract and Chloroform Fraction of <i>Gardenia ternifolia</i> Leaves in <i>Plasmodium berghei</i> Infected Mice.

Aragaw Tezera Jemere TJ Afework Dessie Tegegne DT Getahun Kefyalew Ayalew KA

Evidence-based complementary and alternative medicine : eCAM 20201229

<h4>Background</h4><i>Gardenia ternifolia</i> is utilized in traditional medicine of Ethiopia for malaria treatment and possessing in vitro antimalarial activity. However, no in vivo study was conducted to substantiate the claim. The aim of this study was to judge the antimalarial activity of <i>Gardenia ternifolia</i> extract in vivo in <i>Plasmodium berghei</i>-infected mice.<h4>Methods</h4><i>Plasmodium berghei</i> was inoculated to healthy mice, and hydromethanolic crude extract and chlorofo ...[more]

PMID: 33456487

Similar Datasets

Project description:Background:Malaria is among the leading causes of mortality and morbidity. Moreover, the emergence of resistance to antimalarial drugs is a major problem in controlling the disease. This makes the development of novel antimalarial drugs a necessity. Medicinal plants are important sources in discovering antimalarial drugs. Schinus molle is claimed for its antimalarial effect in Ethiopian folkloric medicine and endowed with in vitro antiplasmodial activity. In the present study, the in vivo antimalarial activity of the plant was investigated. Methods:Acute toxicity was carried out using a standard procedure. To screen the in vivo antimalarial activity of the plant was investigated. S. molle against Plasmodium berghei (ANKA), a 4-day suppressive test was employed. The extracts and fractions were given to infected mice by oral gavage at 100, 200, and 400?mg/kg/day for four consecutive days. Parameters such as parasitemia were then evaluated. Results:Any sign of toxicity was not observed in the oral acute toxicity test. The crude extracts and solvent fractions exerted a significant (p < 0.05) inhibition of parasite load compared to the negative control. The highest inhibition (66.91%) was exhibited by the 400?mg/kg/day dose of 80% methanolic crude extract. Among the fractions, chloroform fraction demonstrated maximal chemosuppressive effect (55.60%). Moreover, crude extracts and solvent fractions prevented body weight loss, reduction in temperature, and anemia compared to the negative control. Except the aqueous fraction, the tested plant extracts were able to significantly prolong the survival time of infected mice. Conclusion:The findings of the present study confirmed the safety and a promising in vivo antimalarial activity of S. molle, thus supporting the traditional claim and in vitro efficacy. In-depth investigations on the plant, however, are highly recommended.in vivo antimalarial activity of the plant was investigated. S. molle against in vitro antiplasmodial activity. In the present study, the.

Project description:Ziziphus mucronata Willd, also known as "buffalo thorn," belongs to the family Rhamnaceae. Its bark and leaves are used in folk medicine for the treatment of various deficiencies related to nociception, inflammation, mood, and depression. Still, there is a lack of scientific data regarding its potential effect on learning and memory process. The present study was designed to investigate the neuroprotective potential of Ziziphus mucronata (ZM) on learning and memory impairment in a scopolamine-induced model of dementia in mice. The phytochemical analysis revealed five cyclopeptide alkaloids (sanjoinines) in the extract from Ziziphus Mucronata leaves using LC-HRMS, and the structural characterization of these compounds was determined via MS/MS. Alzheimer-type amnesia was induced by an intraperitoneal injection of scopolamine (1?mg/kg) to mice for 7 consecutive days. ZM (150?mg/kg, 300?mg/kg, and 600?mg/kg) and piracetam (150?mg/kg) were orally administrated to mice daily for a period of 14 days. Memory-related behavioural parameters were evaluated using the radial arm maze task for 7 days, Y-maze, and novel object recognition task. At the end of protocol schedule, animals were sacrificed, and the levels of acetylcholinesterase, malondialdehyde, catalase, and superoxide dismutase were determined in brain homogenates. Histological studies of the hippocampus were subsequently performed. The long-term scopolamine-injected group decreased the spontaneous alternation (Y-maze), the discrimination index, and the time taken to explore the new object (novel object recognition task). These effects were significantly reversed by ZM at all the doses tested. In the radial arm maze task, ZM (300 and 600?mg/kg) significantly decreased the working and reference memory errors when compared with the demented group. Scopolamine-mediated changes in AChE activity were also attenuated by ZM in mice. In addition, extract-treated groups showed a significant increase in the level of CAT and SOD activity and decreased levels of MDA in the mice brains, as compared with the control group. The present study suggests that ZM could have an important role in neuroprotection on this scopolamine-induced model of Alzheimer-type dementia.